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Sonography Guided Percutaneous
Radiofrequency Ablation of
Hepatocellular Carcinoma: Effect of
Cooperative Training on the Pretreatment
Assessment of the Operation’s Feasibility
Objective: The aim of this study is to investigate the effects of cooperative
training on the pretreatment assessment of the feasibility to perform
Ultrasonography (US) guided percutaneous radiofrequency ablation for patients
afflicted with hepatocellular carcinoma. 
Materials and Methods: In our prospective study, 146 patients with 200 hepa-
tocellular carcinomas were referred for radiofrequency ablation after triage by
hepatologists. Three radiologists with different levels of experience performed the
planning US before (group I) and after (group II) cooperative training, to evaluate
whether radiofrequency ablation was feasible. The feasibility rates considered eli-
gible according to our criteria were evaluated. In addition, we analyzed the rea-
sons for the lack of feasibility were analyzed. The interobserver agreement for the
assessment of feasibility before and after training was also calculated. 
Results: The overall feasibility rates for both groups was 73%. No significant
difference in the feasibility rates was observed. The feasibility rates of each
observer for group I were 71% (observer 1), 77% (observer 2) and 70% (observer
3) and those for group II were 73%, 76% and 69%, respectively. In the tumors (n
= 164) considered ineligible, the two most common causes for refraining from
performing radiofrequency ablation included non-visualization of the tumor (62%)
and the absence of a safe route for the percutaneous approach (38%). We found
moderate interobserver agreement for all observers before cooperative training
and a good agreement after training.
Conclusion: Although the cooperative training did not affect the feasibility rate
of each observer, it improved the interobserver agreement for assessing the fea-
sibility of performing US guided radiofrequency ablation, which may reduce
unnecessary admission or delayed treatment. 
variety of image-guided tumor ablation techniques have been introduced
over the last decade and they play important roles in the therapeutic
management of malignant hepatic tumors (1 8). Radiofrequency
ablation is one of the local ablation techniques which has received great attention for
the treatment of unresectable malignant hepatic tumors (9 13). Ultrasonography
(US), computed tomography (CT), and magnetic resonance imaging (MRI) can be used
for planning, guiding and monitoring local ablation therapies of hepatic tumors.
Among these, US has been the most widely used as a guiding modality for percuta-
neous radiofrequency ablation (14 17) because of its easy availability and real-time
monitoring capability (4, 18). 
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AFor hepatic tumors to be successfully treated with US
guided percutaneous radiofrequency ablation, the tumors
are required to be clearly demonstrated on the pretreat-
ment planning US and any critical organs or structures
should not be present in the pathway of the radiofrequency
electrode. Therefore, the feasibility and treatment strategy
should be thoroughly evaluated in performing US for the
planning before the procedure (4). We can speculate on the
many physicians performing planning US for the candidates
of radiofrequency ablation before the procedure. The
importance of the operator’s experience with radiofre-
quency ablation has been emphasized in several studies and
there is a significant learning curve for the procedure (19).
Similarly, the feasibility of performing US guided percuta-
neous radiofrequency ablation may vary according to the
accumulated experience of the operators. Thus, we thought
that conducting a cooperative training could reduce the
inter-observer variability of the operators and bring the
reproducibility to an acceptable level when assessing the
feasibility of performing US guided percutaneous radiofre-
quency ablation for treating hepatic tumors. The improve-
ment in the inter-observer agreement could avoid the
unnecessary admission or delayed treatment. To the best of
our knowledge, no study has focused on the feasibility of
performing US guided percutaneous radiofrequency
ablation for treating hepatic tumors.
The purpose of this study was to assess the feasibility of
US guided percutaneous radiofrequency ablation for
treating hepatocellular carcinoma (HCC) with the perfor-
mance of pretreatment planning US. As well we also
evaluated the inter-observer variability among the
operators who had different levels of experience before
and after a cooperative training program. 
MATERIALS AND METHODS
Study Design and Population
This is a nonrandomized prospective study with approval
from the Institutional Review Board and consent from all
the patients. The calculated sample size of cases needed in
each group was 96 before and after cooperative training
with an 80% power value and a 5%  value (the type I
error probability for a two sided test), according to the PS
Power and Sample Size Calculations (version 2.1.30,
Noshville, TN). 
Between September 2003 and August 2004, 200 nodular
HCCs in 146 consecutive patients were prospectively
recruited to undergo planning US before their radiofre-
quency ablation procedures. We only included the patients
who were recommended to undergo US guided percuta-
neous radiofrequency ablation of HCC after a triage by
five hepatologists who had at least 3-years of experience in
referring the patients for US-guided radiofrequency
ablation. Of the 146 patients, 140 (96%) had risk factors of
HCC (liver cirrhosis: 86% and chronic hepatitis: 10%).
The levels of  -fetoprotein (AFP) were highly variable with
a range of 4 12,794 ng/mL (mean: 15 ng/mL). We divided
the patients into two groups: Group I included 74 patients
with 100 nodular HCCs which were evaluated between
September 2003 and February 2004 before the coopera-
tive training. Group II was composed of 72 patients with
100 HCCs who were evaluated between March 2004 and
August 2004 after the cooperative training. The amount of
time between the before and after the cooperative training
was one month. The clinical characteristics of the patients
in each group are summarized in Table 1. All patients had
HCCs detected at contrast-enhanced multiphase helical
CT. The diagnosis of HCC for 13 tumors was assessed by
percutaneous needle biopsy. The remaining 187 tumors
were considered to be HCCs on the basis of imaging
findings (n = 157, characteristic enhancement patterns at
contrast-enhanced multiphasic CT or dynamic contrast-
enhanced MR imaging - hypervascularization during the
hepatic arterial phase, and a wash-out pattern during the
equilibrium phase) and elevated serum tumor marker (n =
5,  -fetoprotein [AFP] level > 400 ng/mL [> 400  g/L]) or
at least two concurrent radiological findings which were
compatible with HCC among CT, MR imaging, US, and
angiography (n = 25) (20). 
All patients met the following criteria for treatment with
percutaneous radiofrequency ablation: the presence of a
single tumor with a maximum diameter not exceeding 5
cm, or the presence of multiple (not more than four)
tumors and each with a maximum diameter not greater
exceeding 3 cm; the absence of portal venous thrombosis
and extrahepatic metastasis; the presence of liver cirrhosis
of Child-Pugh class A or B. Remote recurrent HCCs (n =
88) after hepatectomy (n = 13), percutaneous ethanol
injection therapy (n = 2), transarterial chemoembolization
(TACE) (n = 13), radiofrequency ablation (n = 39) and
combined treatment (n = 21) were also included in the
study irrespective of the prior history of treatment. The
operability of the patients did not affect the inclusion
criteria.
We used 17-gauge internally cooled single or cluster RF
electrodes (Radionics, Burlington, MA) with a 500-kHz
monopolar generator (series CC-3; Radionics) which was
able to produce a 200-W output.
Ultrasonographic Studies
Three abdominal radiologists, who had different levels of
experience for the diagnosis of percutaneous radiofre-
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performed the sonographic examinations for each tumor
by themselves. Immediately after one observer finished the
sonographic examination for each patient, the others
followed within a mean of 5 minutes. They were aware of
the CT findings before conducting the sonographic studies.
Observer 1 (senior attending staff) assessed more than
1,000 cases of percutaneous radiofrequency ablation under
the guidance of US, observer 2 (junior staff) assessed over
150 cases and observer 3 (fellow) had 15 cases of experi-
ence without doing the procedure during the research time.
All the sonographic examinations were performed using
1.0- to 4.0-MHz convex array probes (Acuson-Sequoia
512, Siemens Medical Solutions, Mountain View, CA) or
2.0- to 5.0-MHz curvilinear probes (HDI 5000; Advanced
Technology Laboratories, Philips Medical Systems, Bothell,
WA). Using gray-scale and color Doppler US, the
observers independently evaluated the feasibility of US
guided percutaneous radiofrequency ablation of each
tumor. They also archived the sonographic images of each
tumor on a picture archiving and communication system
(PACS, Centricity Workstation, version 1.0; GE Medical
Systems, Milwaukee, WI). The three radiologists scanned
74 patients with 100 nodular HCCs before the cooperative
training and they decided the feasibility of the procedure
for each patient based on their experience. After the
cooperative training, the remaining 72 patients with 100
HCCs were independently examined by the same three
radiologists. 
After the sonographic examination, they recorded the
results for the feasibility of performing US guided percuta-
neous radiofrequency ablation for each tumor. The
probability of completeness of treatment (i.e. incomplete
ablation or primary effectiveness) did not affect the
feasibility. We simplified the feasibility as “feasible” or
“not feasible”. In general we considered the following
tumors as ineligible for US-guided percutaneous radiofre-
quency ablation: 1) When the critical structures (large
vessels, lung base, gallbladder or gastrointestinal tract) are
located in the presumed electrode pathway (i.e. When the
gallbladder or gastrointestinal tract interrupts the pathway
of electrode, or when we cannot keep away from the
segmental portal vein or main portion of hepatic vein or
vessel greater than 3 mm in diameter); 2) When the tumor
is not visualized on US scans. Whenever the observers
considered that percutaneous radiofrequency ablation was
not feasible, they were asked to describe the reasons why
it was not feasible. This work was done independently by
each observer. After the planning US, the final treatment
methods of these patients or outcome of radiofrequency
ablation were evaluated.
Cooperative Training
The training sessions were performed after the
sonographic studies done for group I (100 nodular HCCs in
74 patients). The modulator (observer 3) arranged the
training and prepared all the necessary data only. All three
observers participated in the cooperative training for four
hours which involved the review of the sonographic
images archived on the PACS workstation for all the cases
which showed different decisions on the feasibility among
the observers. Immediately after reviewing each case, we
discussed the reason for the discrepancy and we tried to
reach a consensus on the feasibility of performing percuta-
neous radiofrequency ablation for cases which were not
the decision of senior staff. We compared the index tumor
on US with the presuming lesion on the CT scan for
evaluation of the reason of non-visualized cases. If the
tumor had low conspicuity, a radiologist tried to make a
higher conspicuity with use of harmonic images and taught
it to other radiologists. We evaluated the location of the
cases which showed a discrepancy in the feasibility
between the operators and analyzed the critical structures
which were obstacles to the the safe route to approach the
index tumor. We discussed if there were an alternative safe
route to approach the tumor. The same process was contin-
ued for the all cases with different decisions on feasibility. 
Data Analysis
The overall feasibility and individual feasibility rates
were evaluated before and after the cooperative training.
Also, the reasons for all the cases in which percutaneous
radiofrequency ablation was considered not feasible were
assessed. Moreover, before and after the cooperative
training, the inter-observer agreement among the three
observers on the feasibility were analyzed. Furthermore,
for the cases with a discrepancy between the three
observers, the characteristics of the tumors were assessed
and the causes of these cases were evaluated. The differ-
ence in the numbers showing a discrepancy were assessed
before and after cooperative training.
Statistical Analysis
The feasibility rates of the observers between the two
groups were statistically analyzed using the Generalized
Estimating Equation (GEE) test. To assess the agreement
between the observers on the feasibility of performing US
guided percutaneous radiofrequency ablation, kappa ( )
values were calculated using a computer program
(MedCalc, version 6.0; Medcalc Software, Mariakerke,
Belgium). A  -value greater than zero was considered to
be indicative of a positive correlation. The inter-observer
agreement was rated as follows: poor,  < 0.20; fair,  =
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0.80; very good,  = 0.81 1.00. This was assessed by
comparing the Cohen’s  coefficients (21, 22) which were
calculated for each pair of observers before and after the
cooperative training. Comparisons between the  values
before and after the cooperative training were performed
using the Z test. 
The numerical formula for the Z test is:
(K1;  value of group I, K2;  value of group II
SE1; standard error of group I, SE2; standard error
of group II) 
A p-value less than 0.05 was considered to indicate a
statistically significant difference. 
RESULTS
The clinical characteristics of the patients, including the
patient profiles and tumor characteristics in the both
groups, were not statistically different (Table 1).
Feasibility of Ultrasonography Guided Percutaneous
Radiofrequency Ablation
The overall feasibility rate judged by the proportion of
the tumors considered eligible for US guided percutaneous
radiofrequency ablation by all three observers (Figs. 1, 2),
was 73% (436/600). The feasibility rates of each observer
for group I were 71% (observer 1; 71/100), 77% (observer
2; 77/100) and 70% (observer 3; 70/100) whereas, for
group II were 73% (observer 1; 73/100), 76% (observer 2;
76/100) and 69% (observer 3; 69/100), respectively. There
was no significant difference in the feasibility rates
between the two groups (GEE test, p > 0.05)
For all the tumors (n = 164) considered ineligible for US
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Table 1. Patient Characteristics of Each Group
Group I (n = 74) Group II (n = 72) p value
Age (years) 35 86 (mean, 50) 35 77 (mean, 50) NS
Sex (M:F) 62:12 63:9 NS
Liver cirrhosis LC-B (%) 45 (60.8) 41 (56.9) NS
LC-C (%) 18 (24.3) 19 (26.4) NS
LC-B, C (%) 02 (2.7) 01 (1.4) NS
Chlid class A (%) 64 (86.5) 63 (87.5) NS
B (%) 10 (13.5) 09 (12.5) NS
Group I (n = 100) Group II (n = 100) p value
Tumor size (cm) 0.8 5.0 (mean, 2.2) 0.8 4.7 (mean, 2.1) NS
Location Segment 1 01 00N S
Segment 2 04 09
Segment 3 08 05
Segment 4 17 16
Segment 5 21 33
Segment 6 13 14
Segment 7 18 09
Segment 8 18 14
Note. Numbers in parenthesis are percentages.
T-test was used (p < .05)
NS; not significant 
Based on Couinaud’s classification (27)
Fig. 1. The histogram shows the feasibility rates assessed by the
three observers with different levels of experience to perform
radiofrequency ablation in liver tumors. No statistical difference in
feasibility rates between the two groups before and after coopera-
tive training was observed (GEE test, p > 0.05).
Z =   
K1 K2
SE1 SE2guided percutaneous radiofrequency ablation by all three
observers, the most common causes for refraining from
performing a radiofrequency ablation procedure included
nonvisualization of the tumor (62%, 102/164) and the
absence of a safe route for the percutaneous approach
(38%, 62/164) (Fig. 3). 
The mean tumor size considered ineligible for US guided
percutaneous radiofrequency ablation was 1.9 cm (range,
0.7  3.4 cm), whereas the mean tumor size considered
eligible was 2.1 cm (range, 0.5  5.0 cm). The difference in
size between the two groups was not statistically significant
(p > 0.05, student T-test). The reasons for the cases which
had no safe treatment route (n = 62) included abuttment
on the large hepatic vessels (n = 23), obscured by the lung
(n = 19), abuttment on the gallbladder (n = 6), abuttment
on the heart (n = 4), exophytic growth (n = 4), abuttment
on the diaphragm (n = 2), attachment to the bowel (n = 2),
and attachment to the inferior vena cava (n = 2). 
After the planning US, 171 patients were treated and
among these, 49% (84/171) underwent US guided percuta-
neous radiofrequency ablation. After radiofrequency
ablation, only 5% (4/84) of patients was a residual tumor
found and those four patients were treated by TACE for
the residual tumor. The rest of the 87 patients were treated
with TACE (n = 66), intra-operative radiofrequency
ablation (n = 7), surgical resection (n = 9), and liver
transplantation (n = 4) (Table 2).
Interobserver Agreement
We found moderate ( -value, 0.41 0.60) inter-
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Fig. 2. 56-year-old man with small hepatocellular carcinoma.
A. Contrast-enhanced transverse CT scan obtained during the hepatic arterial phase shows a 2.0 cm diameter hepatocellular carcinoma
(arrow) in liver segment 8. 
B-D. Pretreatment planning sonographic scans performed by three different observers show an echogenic mass (arrows) in same
corresponding area of liver. All three observers judged that the US guided percutaneous radiofrequency ablation was feasible for this tumor.
CDobserver agreement for all three observers in group I and
good inter-observer agreement ( -value = 0.575) for
group II (Table 2). The  -values between the observers
for group I were 0.575 (observers 1 and 2), 0.495
(observers 1 and 3), and 0.431 (observers 2 and 3),
whereas those for group II had  -values of 0.763
(observers 1 and 2), 0.758 (observers 1 and 3), and 0.676
(observers 2 and 3), respectively. The improvement of
inter-observer agreement between observers 1 and 3, and
2 and 3 was statistically significant (Z-test) (Table 3) before
and after the cooperative training (p < 0.05). The different
kappa values of observers 1 and 2 were not statistically
significant between both groups (p > 0.05).
We observed a significant difference in the number of
lesions n = 32) with different feasibility assessments
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Table 3. Interobserver Agreement of Three Observers Before
and After Cooperative Training
Group I Group II
-value SE -value SE p-value
A and B 0.575 0.097 0.763 0.075 0.063
B and C 0.495 0.098 0.758 0.073 0.016
A and C 0.431 0.107 0.676 0.084 0.036
Note. -values: poor, < 0.20; fair, 0.21 0.40; moderate, 0.41 0.60; 
good, 0.61 0.80; very good, 0.81 1.00 
Z test was used (< 0.05)
Observer 1 (senior attending staff): had more than 1000 cases of
experience for percutaneous radiofrequency ablation under the guidance
of US
Observer 2 (junior staff): had over 150 cases of experience
Observer 3 (fellow): had 15 cases of experience 
Table 2. Final Treatment Method and Outcome of Sonography Guided Percutaneous Radiofrequency Ablation of the Patients
Group I (n = 100) Group II (n = 100)
RFA (n = 84) Complete primary effectiveness (95%, 80/84) 38 42
Residual tumor    (5%, 4/84) 2 2
No RFA (n = 116) Treatment (n = 87) TACE 31 35
IO RFA 3 4
Resection 7 2
LT 04
No treatment or follow-up loss (n = 29) 19 10
Note. Residual tumor; all four patients showed a residual tumor after percutaneous radiofrequency ablation underwent TACE for the treatment of 
residual tumors.
IO RFA; Intraoperative radiofrequency ablation 
LT; liver transplantation
Fig. 3. 58-year-old man with two small hepatocellular carcinomas. 
A. Contrast-enhanced transverse CT scan obtained during hepatic arterial phase shows a 1.5 cm diameter enhancing tumor
(arrowhead) in liver segment 8 and another 1.8 cm in diameter tumor (arrow) in liver segment 7. 
B. Pretreatment planning sonographic scans performed by observer 1 shows tumor (arrow) in liver segment 7 with poor conspicuity. The
tumor of segment 8 was not visible. In addition to non-visualization of tumors, there was no safe path for the electrode due to the
intervening lung base. All three observers considered that US guided percutaneous ablation was not feasible for these tumors.
ABbetween the three observers before the cooperative
training and 18 lesions after the cooperative training (p <
0.05, Chi-square test). The mean diameter of the coinci-
dent cases was 2.2 cm (range, 0.5 5.0 cm) whereas tumors
which had different feasibility assessments were on
average, 1.8 cm (range, 0.7 3.5 cm) (p < 0.05, Mann-
Whitney U test). The frequency of tumor locations was
27% in the left hepatic lobe and 73% in the right hepatic
lobe for coincident cases, whereas the frequency was 36%
in the left lobe and 64% in the right lobe for tumor with
different feasibility assessments. Before the cooperative
training, the most common cause of discrepancy was the
ability of localization of the index tumor (72%) and the
second cause was the different decision to approach the
tumor when the critical structures abutted the tumor
(28%) (Fig. 4). After cooperative training, the ability of
localization of the tumor had improved (44%), however,
the improvement was not statistically significant (p > 0.05,
Chi-square). 
DISCUSSION
To the best of our knowledge, this is the first study which
has evaluated the influence of cooperative training on the
assessment of the feasibility for the performance of US
guided percutaneous radiofrequency ablation for HCC
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Fig. 4. Discrepancy in assessing feasibility of US guided percutaneous radiofrequency ablation in a 45-year-old man with hepatocellular
carcinoma.
A. Contrast-enhanced transverse CT scan obtained during hepatic arterial phase shows a 3.5 cm diameter enhancing tumor (arrow) in
liver segment 8. 
B-D. On the pretreatment planning sonographic scans performed by observer 1 (B), observer 2 (C), and observer 3 (D), the tumor
(arrows) is well delineated as hypoechoic mass. Observer 1 considered that US guided percutaneous radiofrequency ablation was not
feasible because of absence of a safe path resulting from the position of the hepatic vein (arrowheads) in B surrounding the tumor. The
other two observers thought that the procedure was feasible.
CDaccording to operators who have different levels of experi-
ence. A learning curve effect regarding the procedure itself
has been addressed in another study on the radiofrequency
ablation for liver tumors (19). 
Radiofrequency ablation has generally been performed
with the use of the image guided percutaneous approach
(13, 14, 23). US is now accepted as the most popular
guiding technique for percutaneous radiofrequency
ablation due to its many advantages (4, 14 18). Imaging is
used in five separate and distinct ways: planning, targeting,
monitoring, controlling and assessing treatment response
(4, 24). Imaging aspects are important for planning when
measuring the size, shape, number and location of the
lesions relative to the critical structures due to the risk of
injury during ablation. Accurate targeting during the
ablation usually depends on the pretreatment planning,
and the accuracy of targeting will determine the treatment
response. Therefore, the pretreatment planning US is very
important for evaluating the feasibility of US guided
percutaneous radiofrequency ablation. Although the
percutaneous radiofrequency ablation has been proved
safe in many clinical trials, previous reports have not
emphasized the importance of operator experience in
radiofrequency ablation for hepatic tumors; thus, more
attention is occasionally paid to the results and efficacy of
the radiofrequency ablation procedure than to the training
and experience of the operators. Among the various
imaging modalities, the US-guided technique is the most
subjective and operator-dependent relative to other
modalities such as MRI or CT (25). The results of our study
emphasize the importance of cooperative training in order
to reduce the inter-observer variability when assessing the
feasibility of performing US guided radiofrequency
ablation for liver tumors. 
By conducting cooperative training among the many
operators with different levels of experience, we could
attain an acceptable level of reproducibility for all levels of
experience. In our institution, many radiologists who have
different levels of experience carry out the procedures,
from senior staff members with expertise, to fellows with
little experience in radiofrequency ablation. When an
inexperienced operator performs the procedure, another
experienced operator usually supervises them through the
entire process of the procedure. There are times when the
operators are different from the persons who performed
the pretreatment planning US. Consequently, discrepan-
cies in the assessment of the feasibility may happen (Fig.
4). These discrepancies may result in unnecessary
admission or delayed treatment. When the patients were
not considered good candidates for the US guided percuta-
neous radiofrequency ablation, we usually recommended
other therapeutic modalities including surgery, intra-
operative radiofrequency ablation or trans-arterial
chemoembolization. These modalities; however, should be
scheduled in advance before admission. 
In our study, the effect of cooperative training was
substantial for observer 3. The change in inter-observer
agreement after cooperative training between observers 1
and 2 was not statistically significant, whereas those
between observers 1 and 3, and observers 2 and 3 were
statistically significant. These results demonstrate that the
least experienced operator obtains the greatest benefit
from cooperative training. The recent studies (19, 26)
suggested that the radiofrequency ablation procedure
involves a significant learning curve and cumulative
experience of the procedures could decrease the procedure
time, complications and increase the success rate of
treatment.
The interesting finding in our study was that there was
no significant difference in the proportion of the tumors
considered feasible for US guided percutaneous radiofre-
quency ablation among the three operators. This means
that approximately a quarter of the tumors referred by the
hepatologists are not eligible for the US guided percuta-
neous radiofrequency ablation, regardless of the operator’s
level of experience. We believe that this observation is an
inherent limitation of US guided radiofrequency ablation
for HCC in the patients with cirrhosis. The most common
cause of a lack of feasibility for US guided radiofrequency
ablation was non-visualization of the tumor with US. It is
often difficult to obtain good conspicuity of a tumor with
sonographic scanning because of the poor sonic window in
the patients with advanced liver cirrhosis, even if the
tumor is well delineated at CT. The second common cause
for the ineligibility of the condition was the lack of a
guaranteed safe route to place the electrode into the
tumor, which is essential to the minimization or prevention
unintended major complications, including bleeding or
injury to the critical structures. 
This limitations of this study are the following: First, the
patients in the both groups before and after cooperative
training were not identical and the differences may have
had an influence on the effect of cooperative training. The
ideal design is to perform the study on the same patients to
avoid the selection bias. However, this would be not
possible due to ethical issues: HCC should be treated
without delay once it is diagnosed. In this study, there was
no statistically significant difference for the clinical charac-
teristics between the two groups, which could have
minimized the selection bias. Second, the true learning
curve for performing pretreatment planning US for US
guided percutaneous radiofrequency ablation was not
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study and it should be addressed in future studies. Third,
since the group I patients were evaluated earlier than the
group II, we could not assess the bias of the temporal
learning curve, which most greatly affects observer 3 who
has the least experienced observer.
In summary, for the pretreatment planning US, 73% of
the referred tumors were considered eligible for the US
guided percutaneous radiofrequency ablation. Moderate
agreement was found among the three operators to assess
the feasibility of US guided percutaneous radiofrequency
ablation for HCC before the cooperative training.
Conducting cooperative training among the operators with
different levels of experience was helpful, to a good
degree, for improving the inter-observer agreement, which
may reduce the unnecessary admission or delayed
treatment. 
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